The current financial score of Harmony Biosciences Holdings Inc is 9.28. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 261.28M, representing a year-over-year increase of 30.32%, while its net profit experienced a year-over-year increase of 89.64%.
The current valuation score of Harmony Biosciences Holdings Inc is 8.06. Its current P/E ratio is 16.43, which is 22.30% below the recent high of 20.09 and 53.72% above the recent low of 7.60.
The current earnings forecast score of Harmony Biosciences Holdings Inc is 7.45. The average price target is 47.36, with a high of 70.00 and a low of 30.00.
The current price momentum score of Harmony Biosciences Holdings Inc is 3.62. Currently, the stock price is trading between the resistance level at 44.18 and the support level at 38.17, making it suitable for range-bound swing trading.
The current institutional shareholding score of Harmony Biosciences Holdings Inc is 10.00. The latest institutional shareholding proportion is 104.28%, representing a quarter-over-quarter increase of 18.29%. The largest institutional shareholder is Chuck Royce, holding a total of 362.46K shares, representing 0.11% of shares outstanding, with 261.32% increase in holdings.
The current risk assessment score of Harmony Biosciences Holdings Inc is 7.60. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.